CCM
Cutter Capital Management Portfolio holdings
AUM
$230M
This Quarter Return
+2.55%
1 Year Return
+11.51%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$259M
AUM Growth
+$259M
(+24%)
Cap. Flow
+$54.7M
Cap. Flow
% of AUM
21.08%
Top 10 Holdings %
Top 10 Hldgs %
58.37%
Holding
36
New
12
Increased
9
Reduced
4
Closed
10
Top Buys
| 1 |
Gilead Sciences
GILD
|
$19.4M |
| 2 |
Bristol-Myers Squibb
BMY
|
$16.6M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$15.7M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$12.5M |
| 5 |
Sarepta Therapeutics
SRPT
|
$12.2M |
Top Sells
| 1 |
Amgen
AMGN
|
$16.5M |
| 2 |
Merck
MRK
|
$14.8M |
| 3 |
Amicus Therapeutics
FOLD
|
$13.4M |
| 4 |
Roivant Sciences
ROIV
|
$11.2M |
| 5 |
Pfizer
PFE
|
$7.63M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $24.2M | 9.27% | 446,900 +306,900 | +219% | +$16.6M |
|
|
2
Gilead Sciences
GILD
$140B
| $19.4M | 7.43% | +265,436 | New | +$19.4M |
|
3
Teva Pharmaceuticals
TEVA
$21.1B
| $16M | 6.13% | 1,135,710 +74,042 | +7% | +$1.04M |
|
|
4
Regeneron Pharmaceuticals
REGN
$61.5B
| $15.7M | 6.02% | +16,360 | New | +$15.7M |
|
5
BioMarin Pharmaceuticals
BMRN
$11.2B
| $15.3M | 5.84% | 175,000 +45,094 | +35% | +$3.94M |
|
|
6
Ionis Pharmaceuticals
IONS
$6.8B
| $12.5M | 4.8% | +289,366 | New | +$12.5M |
|
7
Royalty Pharma
RPRX
$15.6B
| $12.5M | 4.78% | 411,540 +41,540 | +11% | +$1.26M |
|
|
8
Sarepta Therapeutics
SRPT
$1.78B
| $12.2M | 4.67% | +94,379 | New | +$12.2M |
|
9
Acadia Pharmaceuticals
ACAD
$4.38B
| $12.2M | 4.66% | 658,409 +327,436 | +99% | +$6.05M |
|
10
Biogen
BIIB
$19.4B
| $11.2M | 4.29% | +52,000 | New | +$11.2M |
|
11
BioCryst Pharmaceuticals
BCRX
$1.74B
| $10.7M | 4.09% | 2,105,459 +583,647 | +38% | +$2.96M |
|
12
Halozyme
HALO
$8.56B
| $10.4M | 3.97% | 255,049 +14,601 | +6% | +$594K |
|
13
Perrigo
PRGO
$3.27B
| $10.4M | 3.96% | 322,114 +62,114 | +24% | +$2M |
|
14
Exelixis
EXEL
$10.1B
| $9.46M | 3.62% | 398,762 -63,543 | -14% | -$1.51M |
|
|
AVDL
15
Avadel Pharmaceuticals
AVDL
$1.43B
| $9.15M | 3.5% | +541,926 | New | +$9.15M |
|
16
Eli Lilly
LLY
$657B
| $8.59M | 3.28% | +11,040 | New | +$8.59M |
|
17
Agios Pharmaceuticals
AGIO
$2.19B
| $8.44M | 3.23% | +288,580 | New | +$8.44M |
|
18
CRISPR Therapeutics
CRSP
$4.71B
| $8.19M | 3.13% | 120,185 +12,685 | +12% | +$865K |
|
19
Arcellx
ACLX
$3.85B
| $7.44M | 2.85% | +107,000 | New | +$7.44M |
|
20
Insmed
INSM
$28.8B
| $6.17M | 2.36% | 227,337 -186,162 | -45% | -$5.05M |
|
21
Viridian Therapeutics
VRDN
$1.5B
| $4.88M | 1.87% | 278,638 -29,083 | -9% | -$509K |
|
22
Legend Biotech
LEGN
$6.41B
| $4.48M | 1.71% | +79,830 | New | +$4.48M |
|
23
Kyverna Therapeutics
KYTX
$160M
| $4.14M | 1.58% | +166,514 | New | +$4.14M |
|
24
Pliant Therapeutics
PLRX
$101M
| $2.89M | 1.11% | +194,119 | New | +$2.89M |
|
25
Cabaletta Bio
CABA
$133M
| $2.69M | 1.03% | 157,964 -72,036 | -31% | -$1.23M |
|